Lifarizine FA

SKU: orb1819273

Description

Lifarizine FA is a sodium channel blocking agent used in research models of neurological and cardiovascular disorders. Its application extends to in vitro and in vivo studies investigating neuroprotection, particularly in the context of ischemic stroke pathology.

Research Area

Pharmacology & Drug Discovery

Key Properties

• MW: 482.62
• Purity: 99.41% (May vary between batches)
• Formula: C₃₀H₃₄N₄O₂
• SMILES: CC1=C(CN2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)NC(C5=CC=C(C)C=C5)=N1.OC=O
• Target: Sodium Channel
• Solubility: DMSO:55 mg/mL (113.96 mM)

Bioactivity

• In Vivo:
  Following the global ischaemic insult the rats were allowed to recover for 72 h before assessment of the damage, during which time one group of rats (n = 11) received 100 micrograms kg-1 lifarizine i.a. 5 min post-occlusion, 500 micrograms kg-1 lifarizine i.p. 15 min post-occlusion, and 500 micrograms kg-1 lifarizine i.p. twice daily for 72 h. A second group of rats (n = 12) was treated with appropriate volumes of vehicle (0.4 ml kg-1 i.a. and 2 ml kg-1 i.p.) at identical time points. The dosing regimen of lifarizine gave reduced damage in the hippocampal CA1 sub-field (4.1 +/- 0.3 to 2.8 +/- 0.6) and striatum (1.7 +/- 0.3 to 1.2 +/- 0.3) and significant neuroprotection in the anterior cortex (2.0 +/- 0.2 to 1.2 +/- 0.2; p < 0.05), thalamus (1.5 +/- 0.2 to 0.8 +/- 0.2; p < 0.01), posterior cortex (1.5 +/- 0.2 to 1.0 +/- 0.2; p < 0.05) and cerebellar brain stem (0.9 +/- 0.2 to 0.4 +/- 0.1; p < 0.01). The overall mean brain score was significantly reduced (from 1.5 +/- 0.1 to 0.9 +/- 0.2). These data show that the newly modified 2-vessel occlusion model produced a quantifiable level of ischaemic damage and that the novel agent lifarizine is neuroprotective in the model.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Lifarizine FA, Lifarizine FA(119514-66-8 Free base), Sodium Channel, SodiumChannel

Compound Identifiers

PubChem CID

169553388